{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:27:42Z","timestamp":1792808862135,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-99622-4","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T03:45:05Z","timestamp":1747107905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials"],"prefix":"10.1038","volume":"15","author":[{"given":"Shike","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suren Rao","family":"Sooranna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"8","key":"99622_CR1","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1210\/js.2019-00078","volume":"3","author":"SF Witchel","year":"2019","unstructured":"Witchel, S. F., Oberfield, S. E. & Pe\u00f1a, A. S. Polycystic ovary syndrome: Pathophysiology, presentation, and treatment with emphasis on adolescent girls. J. Endocr. Soc. 3 (8), 1545\u20131573 (2019).","journal-title":"J. Endocr. Soc."},{"key":"99622_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jsbmb.2018.04.008","volume":"182","author":"S Patel","year":"2018","unstructured":"Patel, S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J. Steroid Biochem. Mol. Biol. 182, 27\u201336 (2018).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"99622_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1741-7015-8-41","volume":"8","author":"H Teede","year":"2010","unstructured":"Teede, H., Deeks, A. & Moran, L. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8 (1), 41 (2010).","journal-title":"BMC Med."},{"key":"99622_CR4","doi-asserted-by":"crossref","unstructured":"Frankowski, R. et al. Type 2 diabetes mellitus, Non-Alcoholic fatty liver disease, and metabolic repercussions: The vicious cycle and its interplay with inflammation. Int. J. Mol. Sci. 24(11), 9677 (2023).","DOI":"10.3390\/ijms24119677"},{"issue":"10","key":"99622_CR5","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/j.1471-0528.2006.01008.x","volume":"113","author":"FJ Broekmans","year":"2006","unstructured":"Broekmans, F. J. et al. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. Bjog 113 (10), 1210\u20131217 (2006).","journal-title":"Bjog"},{"issue":"1","key":"99622_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-022-01073-0","volume":"7","author":"M Li","year":"2022","unstructured":"Li, M. et al. Trends in insulin resistance: Insights into mechanisms and therapeutic strategy. Signal. Transduct. Target. Ther. 7 (1), 216 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"99622_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0889-8545(05)70187-X","volume":"28","author":"K Hoeger","year":"2001","unstructured":"Hoeger, K. Obesity and weight loss in polycystic ovary syndrome. Obstet. Gynecol. Clin. North. Am. 28 (1), 85\u201397 (2001). vi-vii.","journal-title":"Obstet. Gynecol. Clin. North. Am."},{"issue":"3","key":"99622_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s12011-023-03744-7","volume":"202","author":"S Shahmoradi","year":"2024","unstructured":"Shahmoradi, S. et al. The effect of magnesium supplementation on insulin resistance and metabolic profiles in women with polycystic ovary syndrome: A randomized clinical trial. Biol. Trace Elem. Res. 202 (3), 941\u2013946 (2024).","journal-title":"Biol. Trace Elem. Res."},{"issue":"7","key":"99622_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.tcm.2019.08.010","volume":"30","author":"O Osibogun","year":"2020","unstructured":"Osibogun, O., Ogunmoroti, O. & Michos, E. D. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends Cardiovasc. Med. 30 (7), 399\u2013404 (2020).","journal-title":"Trends Cardiovasc. Med."},{"issue":"2","key":"99622_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrm1837","volume":"7","author":"CM Taniguchi","year":"2006","unstructured":"Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signalling pathways: Insights into insulin action. Nat. Rev. Mol. Cell. Biol. 7 (2), 85\u201396 (2006).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"2","key":"99622_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jcmgh.2018.10.016","volume":"7","author":"D Santoleri","year":"2019","unstructured":"Santoleri, D. & Titchenell, P. M. Resolving the paradox of hepatic insulin resistance. Cell. Mol. Gastroenterol. Hepatol. 7 (2), 447\u2013456 (2019).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"99622_CR12","doi-asserted-by":"publisher","first-page":"100594","DOI":"10.1016\/j.repbio.2021.100594","volume":"22","author":"R Guo","year":"2022","unstructured":"Guo, R. et al. Melatonin alleviates insulin resistance through the PI3K\/AKT signaling pathway in ovary granulosa cells of polycystic ovary syndrome. Reprod. Biol. 22 (1), 100594 (2022).","journal-title":"Reprod. Biol."},{"issue":"10","key":"99622_CR13","doi-asserted-by":"publisher","first-page":"e1475","DOI":"10.1038\/cddis.2014.400","volume":"5","author":"M Shen","year":"2014","unstructured":"Shen, M. et al. Involvement of FoxO1 in the effects of follicle-stimulating hormone on Inhibition of apoptosis in mouse granulosa cells. Cell. Death Dis. 5 (10), e1475 (2014).","journal-title":"Cell. Death Dis."},{"key":"99622_CR14","doi-asserted-by":"crossref","unstructured":"Sun, Z. et al. GLP-1\/GLP-1R Signaling regulates ovarian PCOS-associated granulosa cells proliferation and antiapoptosis by modification of forkhead box protein O1 phosphorylation sites. Int. J. Endocrinol. 2020, 1484321 (2020).","DOI":"10.1155\/2020\/1484321"},{"issue":"5","key":"99622_CR15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/MOP.0000000000000945","volume":"32","author":"RL Rosenfield","year":"2020","unstructured":"Rosenfield, R. L. Current concepts of polycystic ovary syndrome pathogenesis. Curr. Opin. Pediatr. 32 (5), 698\u2013706 (2020).","journal-title":"Curr. Opin. Pediatr."},{"issue":"2","key":"99622_CR16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1210\/jcem.82.2.3727","volume":"82","author":"AM Fulghesu","year":"1997","unstructured":"Fulghesu, A. M. et al. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82 (2), 644\u2013648 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"99622_CR17","doi-asserted-by":"crossref","unstructured":"Singh, S. et al. Polycystic ovary syndrome: Etiology, current management, and future therapeutics. J. Clin. Med. 12(4), 1454 (2023).","DOI":"10.3390\/jcm12041454"},{"key":"99622_CR18","doi-asserted-by":"publisher","first-page":"945609","DOI":"10.3389\/fendo.2022.945609","volume":"13","author":"C Xing","year":"2022","unstructured":"Xing, C., Zhao, H., Zhang, J. & He, B. Effect of Metformin versus Metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front. Endocrinol. (Lausanne). 13, 945609 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"99622_CR19","doi-asserted-by":"publisher","first-page":"1203231","DOI":"10.3389\/fnins.2023.1203231","volume":"17","author":"H Xue","year":"2023","unstructured":"Xue, H., Zeng, L., He, H., Xu, D. & Ren, K. Effectiveness of acupuncture as auxiliary combined with Western medicine for epilepsy: A systematic review and meta-analysis. Front. Neurosci. 17, 1203231 (2023).","journal-title":"Front. Neurosci."},{"issue":"9","key":"99622_CR20","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena, G., Hardie, D. G. & Pearson, E. R. The mechanisms of action of Metformin. Diabetologia 60 (9), 1577\u20131585 (2017).","journal-title":"Diabetologia"},{"issue":"1","key":"99622_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","volume":"42","author":"TE LaMoia","year":"2020","unstructured":"LaMoia, T. E. & Shulman, G. I. Cellular and molecular mechanisms of Metformin action. Endocr. Rev. 42 (1), 77\u201396 (2020).","journal-title":"Endocr. Rev."},{"issue":"1","key":"99622_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","volume":"15","author":"AR Meloni","year":"2013","unstructured":"Meloni, A. R., DeYoung, M. B., Lowe, C. & Parkes, D. G. GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells: Mechanism and glucose dependence. Diabetes Obes. Metab. 15 (1), 15\u201327 (2013).","journal-title":"Diabetes Obes. Metab."},{"key":"99622_CR23","doi-asserted-by":"crossref","unstructured":"Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G. & Meczekalski, B. Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies. J. Clin. Med. 12(18), 5915 (2023).","DOI":"10.3390\/jcm12185915"},{"issue":"10","key":"99622_CR24","doi-asserted-by":"publisher","first-page":"108834","DOI":"10.1016\/j.jdiacomp.2024.108834","volume":"38","author":"A de Athayde De Hollanda","year":"2024","unstructured":"de Athayde De Hollanda, A. et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials. J. Diabetes Compl. 38 (10), 108834 (2024).","journal-title":"J. Diabetes Compl."},{"key":"99622_CR25","doi-asserted-by":"publisher","first-page":"1010714","DOI":"10.3389\/fendo.2022.1010714","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Elevated circulating GPHB5 levels in women with insulin resistance and polycystic ovary syndrome: A cross-sectional study and multiple intervention studies. Front. Endocrinol. (Lausanne). 13, 1010714 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"99622_CR26","doi-asserted-by":"crossref","unstructured":"Bednarz, K. et al. The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int. J. Mol. Sci. 23(8), 4334 (2022).","DOI":"10.3390\/ijms23084334"},{"issue":"6","key":"99622_CR27","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.3390\/cimb45060288","volume":"45","author":"A Petrovic","year":"2023","unstructured":"Petrovic, A. et al. The role of GLP1-RAs in direct modulation of lipid metabolism in hepatic tissue as determined using in vitro models of NAFLD. Curr. Issues Mol. Biol. 45 (6), 4544\u20134556 (2023).","journal-title":"Curr. Issues Mol. Biol."},{"issue":"5","key":"99622_CR28","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","volume":"23","author":"VR Aroda","year":"2022","unstructured":"Aroda, V. R., Blonde, L. & Pratley, R. E. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev. Endocr. Metab. Disord. 23 (5), 979\u2013994 (2022).","journal-title":"Rev. Endocr. Metab. Disord"},{"key":"99622_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen, L. B. & Lau, J. The discovery and development of liraglutide and semaglutide. Front. Endocrinol. (Lausanne). 10, 155 (2019).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"99622_CR30","doi-asserted-by":"publisher","first-page":"101819","DOI":"10.1016\/j.pmedr.2022.101819","volume":"27","author":"N Thongtang","year":"2022","unstructured":"Thongtang, N., Sukmawan, R., Llanes, E. J. B. & Lee, Z-V. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Prev. Med. Rep. 27, 101819 (2022).","journal-title":"Prev. Med. Rep."},{"issue":"3\u20134","key":"99622_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos, T. D., Panagiotopoulou, T. V. & Elisaf, M. S. Adverse effects of GLP-1 receptor agonists. Rev. Diabet. Stud. 11 (3\u20134), 202\u2013230 (2014).","journal-title":"Rev. Diabet. Stud."},{"issue":"3","key":"99622_CR32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/dom.12824","volume":"19","author":"K Bettge","year":"2017","unstructured":"Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J. & Nauck, M. A. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes. Metab. 19 (3), 336\u2013347 (2017).","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"99622_CR33","doi-asserted-by":"publisher","first-page":"e13704","DOI":"10.1111\/obr.13704","volume":"25","author":"A Goldberg","year":"2024","unstructured":"Goldberg, A. et al. Anti-obesity Pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes. Rev. 25 (5), e13704 (2024).","journal-title":"Obes. Rev."},{"issue":"7","key":"99622_CR34","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1210\/jc.2008-0115","volume":"93","author":"K Elkind-Hirsch","year":"2008","unstructured":"Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D. & Bhushan, R. Comparison of single and combined treatment with exenatide and Metformin on menstrual Cyclicity in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93 (7), 2670\u20132678 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"99622_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","volume":"118","author":"KE Elkind-Hirsch","year":"2022","unstructured":"Elkind-Hirsch, K. E., Chappell, N., Shaler, D., Storment, J. & Bellanger, D. Liraglutide 3\u00a0mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: A randomized placebo-controlled-phase 3 study. Fertil. Steril. 118 (2), 371\u2013381 (2022).","journal-title":"Fertil. Steril."},{"issue":"1","key":"99622_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1530\/EC-17-0327","volume":"7","author":"S Fr\u00f8ssing","year":"2018","unstructured":"Fr\u00f8ssing, S., Nylander, M., Kistorp, C., Skouby, S. O. & Faber, J. Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. Endocr. Connect. 7 (1), 115\u2013123 (2018).","journal-title":"Endocr. Connect."},{"issue":"3","key":"99622_CR37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-13-0797","volume":"170","author":"M Jensterle Sever","year":"2014","unstructured":"Jensterle Sever, M., Kocjan, T., Pfeifer, M., Kravos, N. A. & Janez, A. Short-term combined treatment with liraglutide and Metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to Metformin. Eur. J. Endocrinol. 170 (3), 451\u2013459 (2014).","journal-title":"Eur. J. Endocrinol."},{"key":"99622_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13048-015-0161-3","volume":"8","author":"M Jensterle","year":"2015","unstructured":"Jensterle, M., Salamun, V., Kocjan, T., Vrtacnik Bokal, E. & Janez, A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor Roflumilast is superior to Metformin in weight loss in obese PCOS women: A pilot randomized study. J. Ovarian Res. 8, 32 (2015).","journal-title":"J. Ovarian Res."},{"issue":"1","key":"99622_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF03401383","volume":"14","author":"M Jensterle","year":"2015","unstructured":"Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T. & Janez, A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Horm. (Athens). 14 (1), 81\u201390 (2015).","journal-title":"Horm. (Athens)"},{"key":"99622_CR40","doi-asserted-by":"publisher","first-page":"108935","DOI":"10.1016\/j.diabres.2021.108935","volume":"178","author":"M Jensterle","year":"2021","unstructured":"Jensterle, M. et al. Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. Diabetes Res. Clin. Pract. 178, 108935 (2021).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"99622_CR41","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/dom.14944","volume":"25","author":"M Jensterle","year":"2023","unstructured":"Jensterle, M. et al. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes. Metab. 25 (4), 975\u2013984 (2023).","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"99622_CR42","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00404-022-06700-3","volume":"306","author":"R Li","year":"2022","unstructured":"Li, R., Mai, T., Zheng, S. & Zhang, Y. Effect of Metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: Long-term follow-up of an RCT. Arch. Gynecol. Obstet. 306 (5), 1711\u20131721 (2022).","journal-title":"Arch. Gynecol. Obstet."},{"issue":"6","key":"99622_CR43","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/cen.13454","volume":"87","author":"X Liu","year":"2017","unstructured":"Liu, X. et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight\/obese polycystic ovary syndrome. Clin. Endocrinol. (Oxf). 87 (6), 767\u2013774 (2017).","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"2","key":"99622_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EC-16-0113","volume":"6","author":"M Nylander","year":"2017","unstructured":"Nylander, M., Fr\u00f8ssing, S., Kistorp, C., Faber, J. & Skouby, S. O. Liraglutide in polycystic ovary syndrome: A randomized trial, investigating effects on thrombogenic potential. Endocr. Connect. 6 (2), 89\u201399 (2017).","journal-title":"Endocr. Connect."},{"issue":"3","key":"99622_CR45","doi-asserted-by":"publisher","first-page":"e1420","DOI":"10.1210\/clinem\/dgaa692","volume":"106","author":"T Tao","year":"2021","unstructured":"Tao, T. et al. Exenatide, Metformin, or both for prediabetes in PCOS: A randomized, Open-label, Parallel-group controlled study. J. Clin. Endocrinol. Metab. 106 (3), e1420\u2013e1432 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"99622_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.obmed.2017.06.003","volume":"7","author":"S Zheng","year":"2017","unstructured":"Zheng, S. et al. Short term monotherapy with exenatide is superior to Metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight\/obese PCOS women. Obes. Med. 7, 15\u201320 (2017).","journal-title":"Obes. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99622-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99622-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99622-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T16:01:55Z","timestamp":1747497715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99622-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["99622"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-99622-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"16512"}}